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Abstract
Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its
stimulation by endogenous ligands, EGF or transforming growth factor-alpha (TGF-α) results in
activation of intracellular tyrosine kinase, therefore, cell cycle progression. High levels of EGFR
expression are correlated with poor prognosis and resistance to radiation therapy in a variety of
cancers, mostly in squamous-cell carcinoma of the head and neck (SCCHN). Blocking the EGFR by
a monoclonal antibody results in inhibition of the stimulation of the receptor, therefore, in
inhibition of cell proliferation, enhanced apoptosis, and reduced angiogenesis, invasiveness and
metastases. The EGFR is a prime target for new anticancer therapy in SCCHN, and other agents
in development include small molecular tyrosine kinase inhibitors and antisense therapies.
Review
Squamous-cell carcinoma of the head and neck (SCCHN)
remains a challenging clinical problem, due to the persist-
ing high rate of local and distant failure, as well as the
occurrence of second primaries. Treatment for early stage
disease involves usually surgery and radiation therapy
(RT). Locally-advanced tumors are best treated with con-
current chemotherapy to RT, either in the definitive set-
ting or following surgery, according to each center's
expertise.
Although altered radiation fractionation and chemoradi-
otherapy had a favorable impact for advanced head and
neck cancer patients, the outcome of patients presenting
with stage III-IV SCCHN is still poor, with 5-year actuarial
survival rates fluctuating between 30% and 40% in most
trials [1].
Recent research efforts have attempted to exploit biologic
differences that may exist between normal and malignant
cells, to develop tumor-specific therapies. The epidermal
growth factor (EGF) and its receptor (EGFR, ErbB-1, or
HER-1) were not only shown to play an influential role in
cellular growth and differentiation in healthy tissues, but
also in tumorigenesis and the progression of malignant
disease [2].
As well as being expressed on the surface of healthy cells,
the EGFR is commonly expressed at high levels in a variety
of epithelial tumors, including SCCHN. The aberrant acti-
vation of the EGFR leads to enhanced proliferation and
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other tumour-promoting activities, which provide a
strong rationale to target this receptor.
During the past decade, intense research has initiated a
new era of cancer treatment, that of molecular therapeu-
tics. Today, the EGFR is a prime target for new anticancer
therapy, with a broad range of inhibitors currently under
investigation [3].
Promising preclinical studies have prompted the develop-
ment of clinical trials testing EGFR inhibitors as single-
agent therapy or in combination with conventional cyto-
toxic therapy, with response rates lower than anticipated
in the advanced disease setting. The clearest benefit of
EGFR-inhibitor treatment to date is noted when it is com-
bined with RT to treat locally advanced head and neck
cancer [4].
The epidermal growth factor receptor
It was not until 1980 that Cohen et al managed to purify
the EGFR [5], 15 years after the initial isolation of its lig-
and, EGF [6]. EGFR is a glycoprotein of 170 kDa, encoded
by a gene located on chromosome 7p12 [7]. It belongs to
the ErbB receptor family (EGFR or Her-1, Her-2, Her-3,
and Her-4). These receptors are composed of an extra-cel-
lular ligand-binding domain, a hydrophobic transmem-
brane segment, and an intracellular tyrosine kinase
domain.
Binding to EGFR by its natural ligands, mainly EGF or
transforming growth factor alpha (TGF-α) results in a con-
formational change in the receptor, which promotes
homodimerization with other EGFR molecules or het-
erodimerization with other HER family members (espe-
cially Her-2); dimerization results in subsequent
autoactivation of the tyrosine kinase from the intracellular
domain of the receptor. This process will activate an intra-
cellular signalling pathway, leading to the inhibition of
apoptosis, activation of cell proliferation and angiogen-
esis, as well as an increase in metastatic spread potential
[8].
The radiobiological rationale
The effect of radiation on tumor-cell proliferation has
been extensively studied in the setting of RT of the head
and neck. Accelerated repopulation, a condition of
enhanced cellular proliferation after exposure to ionising
radiation, appears to be responsible, at least in part, for
radioresistance of head and neck cancers. Preclinical evi-
dence suggests that EGFR has an important role in the pro-
liferative response to ionizing radiation, counteracting the
toxic effects of RT. Mechanisms of activation may be
diverse, including increased EGFR expression [9] but one
key mechanism involves probably ligand-stimulated acti-
vation.
RT is able indeed to activate early the transduction signal-
ling pathway of EGFR, through radiation-induced release
of TGF-α, one of the EGFR ligands [10].
The inhibition of radiation-induced activation of the
EGFR signalling pathway is one of the factors explaining
the observed synergy between RT and EGFR inhibition; an
increase in radiosensitivity through this pathway was
demonstrated in vitro [11]. It has to be reminded that, at
this point, no clear relationship has been demonstrated
between EGFR expression (at least as measured by immu-
nohistochemistry) and the level of radiation sensitization
achieved with anti-EGFR. We are unable as well to identify
tumors that are radioresistant by virtue of EGFR signal-
ling, and are thus likely to become radiosensitized by
EGFR inhibitors [12].
EGFR expression in head an neck cancer
In normal cells, the expression of EGFR ranges from
40,000 to 100,000 receptors per cell [13]. In SCCHN,
EGFR and its ligand, TGF-α, are overexpressed in 80–90%
of cases; the corresponding magnitudes of increase are
1.7-fold (P = 0.005) and 1.9-fold (P = 0.006) respectively,
when compared to controls [14]. The nature of the pro-
tein overexpression is thought to result from enhanced
transcription, with no apparent change in mRNA stability;
gene amplification has been observed less frequently.
TGF-α is participating in an autocrine-signalling pathway
in transformed, but not in normal mucosal epithelial
cells. Targeting the translation start site of TGF-α mRNA
with antisense oligonucleotides decreases TGF-α protein
by up to 93% and reduces cell proliferation by a mean of
76% in human cell lines [15].
EGFR overexpression is an early event in SCCHN carcino-
genesis; it is already present in "healthy" mucosa (field
cancerization) from cancer patients, when compared to
healthy controls; this overexpression will increase steadily
in parallel to observed histological abnormalities, from
hyperplasia to invasive carcinoma, through dysplasia and
in situ carcinoma [16].
Prognostic value of EGFR expression
Most preclinical and clinical studies demonstrated a lower
local control after radiation therapy in tumors overex-
pressing EGFR [17]. A former study in 140 patients with
primary laryngeal squamous-cell carcinoma showed that
the 5-year survival rate was 81% for patients with EGFR
non-expressing tumors, compared with 25% for patients
with EGFR-expressing tumors (P < 0.0001) [18]. These
results were also confirmed by others [19].
A recent retrospective study [20] evaluated the EGFR
expression in 155 patients with stage III-IV SCCHNRadiation Oncology 2006, 1:11 http://www.ro-journal.com/content/1/1/11
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accrued in the control arm of RTOG 9003 study, and
received exclusive external beam RT (70 Gy in 7 weeks). A
detectable expression of EGFR was found in 148/155
patients (95%), with a wide range in interindividual vari-
ability. In this study, EGFR expression was found to be
independent from tumor stage or initial nodal involve-
ment; in multivariated analysis, it showed to be an inde-
pendent pronostic factor of overall survival (P = 0.006),
and of disease-free survival (P = 0.003), as well as a robust
pronostic factor of locoregional relapse (P = 0.002) but
not of distant relapse (P = 0.50).
If quantitative evaluation of EGFR by immunohistochem-
istry has emerged so far as a convenient and promising
marker for clinical outcome correlation, a more accurate
reflection of the "activity state" of EGFR signalling status
might be provided by the phosphorylated or "activated"
forms of EGFR downstream signalling molecules like
phosphorylated MAPK, phosphorylated AKT or Stat-3
[21,22]. They are currently actively evaluated as potential
surrogate markers of EGFR signalling in clinical therapeu-
tic trials.
Inhibition of EGFR activity
Two complementary therapeutic strategies have been
developed. The first one targets the extracellular domain
of the receptor with monoclonal antibodies (cetuximab,
C225, or Erbitux®); binding of the antibody to the EGFR
prevents activation of the receptor by endogeneous lig-
ands through competitive inhibition; it also results in
internalization and degradation of the antibody-receptor
complex, downregulating EGFR expression.
The second strategy targets the intracellular domain of the
receptor with low-molecular-weight tyrosine kinase
inhibitors (gefitinib, ZD 1839, Iressa®; erlotinib, OSI 774,
Tarceva®), competing with adenosine triphosphate (ATP)
for its binding site on the intracellular domain of EGFR.
These two classes of anti-EGFR agents did not meet the
expectations in clinical practice when used in mono-
therapy, resulting more often in a cytostatic than a cyto-
toxic effect [23].
Combining EGFR inhibitors with conventional chemo-
therapy provided disappointing results so far. The Eastern
Cooperative Oncology Group (ECOG) conducted a phase
III study in 121 patients with relapsed or metastatic
SCCHN; patients were randomized between a chemother-
apy-only arm, and an arm combining cisplatin with cetux-
imab. Survival differences were not significant [24].
Cetuximab and radiation therapy
In 2000, Bonner et al demonstrated in a pannel of
SCCHN cell lines that the combination of cetuximab (5
μg/l) delivered simultaneously with radiation (3 Gy)
resulted in a greater decrement in cellular proliferation
than either treatment alone, regardless of the inherent
EGFR expression of the cell line [25]. These promising
results served as preclinical background for clinical inves-
tigations involving C225/radiation in human SCCHN.
The same author conducted a multinational phase III
study involving 424 patients with locoregionally
advanced SCCHN treated with curative intent [4]. Accrual
took place between April 1999 and March 2002. Patients
were randomized between definitive RT, versus the same
RT regimen combined to weekly administration of cetux-
imab. Median follow-up was 54 months. Radiotherapy
plus cetuximab significantly prolonged progression-free
survival (hazard ratio for disease progression or death:
0.70 (0.54–0.90); P = 0.006).
The median duration of overall survival in the definitive
RT arm was 29.3 months, against 49.0 months in the arm
combining radiation therapy plus cetuximab (P = 0.03).
The 3-year survival rate was 45% for patients receiving RT
alone, and 55% for those receving RT and cetuximab.
Grade 3–5 acneiform rash was more common in the arm
with cetuximab (17%) than in the RT alone arm (1%);
this difference was statistically highly significant (P = <
0.001). Importantly, however, the use of cetuximab did
not appear to exacerbate radiation-induced mucositis
(grades 3–5: P = 0.44; all grades: P = 0.84) nor other tox-
icities.
This is the first study to ever demonstrate a survival benefit
related to the administration of an EGFR inhibitor (cetux-
imab) when combined to RT in head and neck cancer,
confirming the promising results provided by previous
phase II clinical studies. Enthusiasm has still to be tem-
pered, as the control arm was unfortunately RT alone and
not concomitant chemoradiation.
It has to be reminded that this trial was designed in an era
when radiation alone was still considered an acceptable
standard in the treatment of advanced head and neck can-
cer patients; in the mean time, concurrent radiochemo-
therapy has assumed a preferred role for these patients.
This trial enabled at least an unencumbered assessment
regarding the capacity of cetuximab to augment radiation
response and outcome without the confounding variable
of chemotherapy [26].
The promising results from this phase III study will still
require further cross-validation through additional trials
to confirm outcome advantage for the combination of
cetuximab with (chemo-) radiation therapy. A broadRadiation Oncology 2006, 1:11 http://www.ro-journal.com/content/1/1/11
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series of new clinical trials is currently under way [Table
1].
Tyrosine kinase inhibitors (TKI) and RT
In preclinical studies, when gefitinib was combined to RT,
strikingly greater than additive effects were observed in
vivo [27].
At the ASCO 2005 meeting, Cohen et al. presented the
results from a phase II study, integrating gefitinib into a
concurrent chemoradiation regimen in patients with
advanced SCCHN, followed by gefitinib alone in the adju-
vant setting [28]. From the 69 patients accrued, only 42
subjects were evaluable for response, with a median fol-
low-up of 10 months (16 patients had not yet been eval-
uated, the others were not evaluable for various reasons).
Grade III-IV toxicities were consistent with previous
chemoradiotherapy trials. Complete response rate (CR)
was 88% (37/42), suggesting that this regimen might be
promising for patients with advanced SCCHN.
No mature data are available regarding erlotinib in com-
bination with (chemo)radiotherapy in advanced SCCHN.
Phase III studies will have to evaluate standard chemora-
diotherapy in combination with TKIs or placebo for
advanced HNSCC, as well as the potential role of these
small molecules in the adjuvant setting.
Conclusion
Despite decades of intensive clinical investigations, the
outcome of patients presenting with stage III-IV HNSCC is
still poor, with 5-year actuarial survival rates fluctuating
between 30% and 40% in most trials. These findings
underscore the need to develop novel strategies in the
management of patients with advanced HNSCC.
Accelerated radiation schemes lead to an enhanced 5-year
local control from 60–70%, associated with an improved
disease-free survival, but with no benefit regarding overall
survival [29].
Clinical trials testing combined modality therapy demon-
strate that cytotoxic drugs given before (induction or neo-
adjuvant chemotherapy) or after (adjuvant
chemotherapy) surgery or radiation do not improve sig-
nificantly the local and distant control of the disease. In
contrast, administering chemotherapy concurrently with
radiation therapy has improved the 5-year overall survival
rate by about 8%, but at the costs of increased local toxic-
ity [30].
The magnitude of the survival benefit in favour of chemo-
radiation is almost identical regardless whether mono-
chemotherapy or poly-chemotherapy is used. Cisplatin
and 5-FU appear to be more effective than carboplatin or
mitomycin C; no randomized data are available for newer
cytostatic drugs like taxanes that have been shown to be
effective in head and neck cancer [31].
Current chemo- and radiation therapies have reached
their limits, with only minor improvements to be
expected in the future; research is currently developing
new treatment strategies, integrating novel targeted thera-
pies in clinical practice.
In SCCHN, EGFR is not only an independent prognostic
factor of outcome in multivariate analysis, but also a first-
choice therapeutic target. The recent demonstration of a
significant survival benefit when combining cetuximab
with external RT is a major breakthrough in the manage-
ment of SCCHN, establishing a new treatment option for
locally advanced SCCHN. This trial provided also an
important proof of principle that targeting a pertinent sig-
nalling pathway can enhance the radiation response of
tumors. However, the improvement in the loco-regional
control rate has been modest (within the range achieved
with concurrent radiotherapy and chemotherapy) and
Table 1: Current phase II/III trials assessing EGFR inhibitors in combination with radiation (RT) locally advanced non-metastatic stage 
IV squamous-cell cancer of the head and neck
Trial Protocol ID EGFR inhibitor Status Comments
Phase III RTOG-0522 Cetuximab Active Concurrent chemoRT +/- C225
Phase II ECOG-E3303 Cetuximab Active Concurrent chemoRT + C225, followed C225 
maintenance
Phase II RTOG-0234 Cetuximab Active Surgery followed by adjuvant chemoRT (cisplatin 
vs. docetaxel) + C225
Phase II NCT00140556 Erlotinib Active Concurrent chemoRT + erlotinib + bevacizumab
Phase II NCT00226239 Cetuximab Active Induction chemotherapy with docetaxel/cisplatin 
+ C225 followed by RT/cisplatin + C225
Phase II NCT00193284 Gefitinib Active Induction chemotherapy with docetaxel/
carboplatin/5-FU + gefitinib followed by RT/
gefitinib +/- docetaxel
EGFR: epidermoid growth factor receptorRadiation Oncology 2006, 1:11 http://www.ro-journal.com/content/1/1/11
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more than half of patients receiving radiotherapy plus
cetuximab still experienced local-regional relapse [4].
Therefore, there is a need to further improve outcome.
Ongoing clinical efforts are devoted to address whether
the addition of cetuximab to concurrent chemoradiation
can yield a better outcome (i.e., RTOG study 0522).
At this point, it has to be reminded that cancer cells rely
on several, sometimes, redundant activation pathways;
EGFR is only one of them. The risk of treatment failure is
real, if only one receptor is targeted, hence the interest in
combining broader range tyrosine kinase inhibitors such
as CI-1033, which targets all four members of the Erb fam-
ily (pan ErbB).
Finally, ionizing radiation stimulates the nitric oxyde
(NO) pathway as well as the production of VEGF [32,33].
Angiogenesis inhibitors bear the potential to reinforce the
cytotoxic action of RT. ZD6474, a small molecule tyrosine
kinase inhibitor of EGFR and VEGF, looks very promising
for the future.
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